Eli Lilly and Novo want to shake off Ozempic copycats. Are they ready to meet demand?
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...
Lilly pill cuts genetic form of cholesterol nearly 86% in study
The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in a mid-stage trial, according to data presented at a medical meeting on ...
Eli Lilly & Co (LLY) Receives a Hold from Evercore ISI
Evercore ISI analyst Umer Raffat maintained a Hold rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last ...
Medicaid dominates coverage of Novo, Lilly weight-loss drugs
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...
Eli Lilly's Lipoprotein(a) Treatment Muvalaplin Meets Primary Endpoint in Trial
Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...
Why Eli Lilly’s CEO says failing faster is essential to the company’s success
On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...
Eli Lilly follows J&J in suing Biden administration over 340B rebates
Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
GlobalData on MSN12h
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF
The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
Yahoo Finance12h
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Eli Lilly (LLY) has recently been on Zacks.com's list of the most ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending ...